AR122725A1 - Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos - Google Patents
Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismosInfo
- Publication number
- AR122725A1 AR122725A1 ARP210101737A ARP210101737A AR122725A1 AR 122725 A1 AR122725 A1 AR 122725A1 AR P210101737 A ARP210101737 A AR P210101737A AR P210101737 A ARP210101737 A AR P210101737A AR 122725 A1 AR122725 A1 AR 122725A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- unsubstituted
- substituted
- cycloalkyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043612P | 2020-06-24 | 2020-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122725A1 true AR122725A1 (es) | 2022-09-28 |
Family
ID=79032406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101737A AR122725A1 (es) | 2020-06-24 | 2021-06-23 | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11739075B2 (https=) |
| EP (1) | EP4171568B1 (https=) |
| JP (1) | JP7778095B2 (https=) |
| KR (1) | KR20230027213A (https=) |
| CN (1) | CN115955979B (https=) |
| AR (1) | AR122725A1 (https=) |
| ES (1) | ES3048462T3 (https=) |
| TW (1) | TW202216681A (https=) |
| WO (1) | WO2021262812A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| WO2022262782A1 (zh) * | 2021-06-17 | 2022-12-22 | 南京明德新药研发有限公司 | 戊二酰亚胺取代的异噁唑稠环化合物及其应用 |
| JP2024534223A (ja) | 2021-09-01 | 2024-09-18 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｂｃｌ－２ファミリータンパク質を分解する化合物及びその医薬的な応用 |
| AU2023278399A1 (en) | 2022-06-02 | 2024-12-19 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for inhibiting or degrading bcl6 and use thereof in pharmaceutics |
| TW202530189A (zh) | 2023-09-29 | 2025-08-01 | 日商第一三共股份有限公司 | ３－苯基丙基胺衍生物 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
| AR088082A1 (es) * | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| WO2015179438A1 (en) * | 2014-05-20 | 2015-11-26 | Ohio State Innovation Foundation | Small molecule rac or rho inhibitors |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110317192A (zh) * | 2018-03-28 | 2019-10-11 | 上海美志医药科技有限公司 | 一类具有降解雄激素受体活性的化合物 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2021
- 2021-06-23 JP JP2022579835A patent/JP7778095B2/ja active Active
- 2021-06-23 CN CN202180044305.0A patent/CN115955979B/zh active Active
- 2021-06-23 ES ES21830097T patent/ES3048462T3/es active Active
- 2021-06-23 TW TW110122924A patent/TW202216681A/zh unknown
- 2021-06-23 WO PCT/US2021/038625 patent/WO2021262812A1/en not_active Ceased
- 2021-06-23 US US17/356,305 patent/US11739075B2/en active Active
- 2021-06-23 EP EP21830097.8A patent/EP4171568B1/en active Active
- 2021-06-23 KR KR1020237002102A patent/KR20230027213A/ko active Pending
- 2021-06-23 AR ARP210101737A patent/AR122725A1/es not_active Application Discontinuation
-
2023
- 2023-07-07 US US18/219,511 patent/US12227490B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115955979A (zh) | 2023-04-11 |
| EP4171568B1 (en) | 2025-08-27 |
| US11739075B2 (en) | 2023-08-29 |
| WO2021262812A1 (en) | 2021-12-30 |
| JP7778095B2 (ja) | 2025-12-01 |
| EP4171568A4 (en) | 2024-07-24 |
| EP4171568A1 (en) | 2023-05-03 |
| TW202216681A (zh) | 2022-05-01 |
| US12227490B2 (en) | 2025-02-18 |
| ES3048462T3 (en) | 2025-12-10 |
| CN115955979B (zh) | 2025-12-05 |
| US20210403453A1 (en) | 2021-12-30 |
| KR20230027213A (ko) | 2023-02-27 |
| JP2023531709A (ja) | 2023-07-25 |
| US20230348431A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122725A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR122723A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR122726A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| PE20200758A1 (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| AR110706A1 (es) | Inhibidores de poli-adp ribosa polimerasa (parp) | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR083058A1 (es) | Compuestos de estructura de imidazotriazinona | |
| AR060633A1 (es) | Derivados de furo[3, 2-d]pirimidina, furo[2, 3-d]pirimidina, tieno[3, 2-d]pirimidina y tieno[2, 3-d]pirimidina, metodos para su preparacion, composiciones farmaceuticas y obtencion de las mismas, el uso de estos derivados en la fabricacion de medicamentos, kits y productos para el tratamiento de enf | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| CL2011002859A1 (es) | Compuestos espironucleosidos, inhibidores del virus vhc; composicion farmaceutica de dichos compuestos; uso del compuesto para tratar la hepatitis c. | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
| PE20161379A1 (es) | Nuevos compuestos macrociclicos | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| PE20081113A1 (es) | Inhibidores virales policiclicos | |
| AR103629A1 (es) | Compuestos con actividad antitumoral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |